Merck's Roger Perlmutter continues spinning deals, putting up $1B+ for Janux Therapeutics and its T cell engagers
Even as his tenure at Merck comes to a close, Roger Perlmutter isn’t finished wheeling and dealing just yet.
Less than a month after …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
